[A18-04] Carfilzomib (multiple myeloma) - Addendum to Commission A17-38
Last updated 15.02.2018
Project no.:
A18-04
Commission:
Commission awarded on 09.01.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with multiple myeloma who have received at least one previous treatment
Combination with lenalidomide and dexamethasone: indication of a considerable added benefit for patients < 65 years and hint of minor added benefit for patients ≥ 65 years. Combination with dexamethasone: indication of minor added benefit.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-38 | Carfilzomib (multiple myeloma) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-02-15 A G-BA decision was published.